Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Washington Post Profiles Operation Rescue Founder Randall Terry
The Washington Post on Wednesday profiled Randall Terry, the founder and former head of the antiabortion-rights group Operation Rescue. According to the Post, Terry is known as a "shock jock of the antiabortion movement" with a "theatrical bent." The Post reports that Terry was arrested dozens of times in the late 1980s and 1990s during his protests. For a short period, his "tactics transformed the antiabortion movement," earning him praise from conservative Christian leaders like Jerry Falwell and Pat Robertson. However, after a 1994 federal law made blocking clinics a federal crime, Terry"s group "started to unravel" after he struggled to pay fines for violating the law. He lost in several lawsuits filed by Planned Parenthood -- resulting in him owing $1.6 million to the group -- and he filed for bankruptcy in 1998. Although Terry left as the leader of Operation Rescue in 1991, he now has moved to the Washington, D.C., area to "try to reclaim the prominence he once enjoyed within the antiabortion movement," an effort he is making "much to the consternation of people on both sides of the abortion debate," according to the Post. Most recently, he has been leading protests outside the confirmation hearings for Supreme Court nominee Sonia Sotomayor. The Post reports that leaders in the antiabortion-rights movement "are cringing at Terry"s sudden return," saying that "his incendiary rhetoric and showy tactics turn off ordinary Americans and reflect Terry"s struggle to regain his glory years." He also is focused on starting a new organization, Operation Rescue Insurrecta Nex, a Latin term translated to mean "insurrection against death" (Salmon, Washington Post, 7/15). The Post also included a timeline of Terry"s personal life and history with the antiabortion-rights movement (Washington Post, 7/15).

Obama Presses Lawmakers On Health Reform
In President Obama"s push for health reform, "new fault lines are opening up everywhere you look. Liberals are worried that Obama is going squishy on including a strong, government-run "public option" among the health-care choices available to Americans. Conservatives are warning that the legislation won"t do enough to control health costs. Rural lawmakers are complaining that proposed Medicare cuts will fall too hard on their states," TIME reports. "And those are just the arguments going on among the Democrats. It"s all a sign that the season for hard decisions has arrived. Obama continues to project an air of confidence about the most audacious undertaking of his presidency" (Tumulty, 7/16).
News of the day
Association For The Treatment Of Tobacco Use And Dependence Supports The FDA Ban Of 'Electronic' Cigarettes
The
Health Insurance

Effects Of Once-Daily Tadalafil On Erectile Function In Men With Erectile Dysfunction And Signs And Symptoms Of Benign Prostatic Hyperplasia

UroToday.com - Men with benign prostatic hyperplasia (BPH) often suffer from lower urinary tract symptoms (LUTS; BPH-LUTS) such as urinary frequency, urgency, intermittency, nocturia, straining, incomplete emptying, or weak urinary stream. BPH-LUTS and erectile dysfunction (ED), both highly prevalent conditions in aging men, are frequently associated in the same men, may have common pathophysiological mechanisms, and contribute negatively to quality of life. Phosphodiesterase type 5 (PDE5) isozymes are considered promising targets for drug intervention in the urogenital tract, and the potential use of PDE5 inhibitors as treatment for both BPH LUTS and ED is of clinical interest. The PDE5 inhibitor tadalafil, currently approved for the treatment of erectile dysfunction and for the treatment of pulmonary arterial hypertension in some geographies, is being studied in men with signs and symptoms of BPH. Tadalafil"s 17.5-hour half-life makes it suitable for once-daily therapy. We report a post hoc analysis of 581 men from a 12-week, randomized, double-blind, placebo-controlled, parallel-group, multinational, dose-finding study of once-daily tadalafil conducted in men with BPH-LUTS. The men included in this analysis were sexually active with a female partner and also had ED, defined as a consistent change in the quality of erection that adversely affected patient satisfaction with sexual intercourse. We evaluated in these men changes in erectile function (International Index of Erectile Function-Erectile Function [IIEF-EF] domain score), changes in BPH-LUTS measures (International Prostate Symptom Score [IPSS], peak urinary flow rate [Qmax], and postvoid residual volume [PVR]), and safety with tadalafil once daily (2.5 mg, 5 mg, 10 mg, or 20 mg) vs. placebo. IIEF EF domain score improvements from baseline with once-daily tadalafil were significantly greater throughout the study for all tadalafil groups vs. placebo (all p values ð‰¤0.001). Once-daily tadalafil also improved IIEF-EF domain scores in clinically important subgroups of patients stratified according to age group, body mass index, BPH-LUTS severity, prostate-specific antigen (a surrogate for prostate size), prior α-blocker use, and prior ED therapy, suggesting that once-daily tadalafil may be effective in treating a broad group of men with BPH-LUTS. IPSS improvements from baseline to end point were significantly greater with all tadalafil doses vs. placebo (all p values UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009